Skip to content

Study · Case report or series · n = 1 · 1991

2 results

Pulmonary endometriosis: conservative treatment with GnRH agonists.

Espaulella J, Armengol J, Bella F, Lain JM, Calaf J

Obstetrics and gynecology1 Sept 1991Cited by 24 (Europe PMC)

PMID1831251 (opens in a new tab)PepBankPUB-01831251
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    A patient with pulmonary endometriosis remained asymptomatic 14 months after stopping triptorelin.

    In plain wordsA patient with pulmonary endometriosis remained symptom-free 14 months after stopping triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePulmonary endometriosis symptoms after cessation
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg/month · intramuscular · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient was then treated with Triptorelin (3.75 mg/month intramuscularly) for 6 months and remains asymptomatic and menstruating 14 months after discontinuing treatment.
    2 context sentences
    Summary · context
    We present two cases of pulmonary endometriosis, parenchymal and pleural.
    Summary · context
    The presenting symptoms were catamenial hemoptysis and pneumothorax, respectively, which were treated with GnRH analogues.
  2. 02HumanCase report or seriesEfficacy outcome

    A patient with pulmonary endometriosis was menstruating 14 months after stopping triptorelin.

    In plain wordsA patient with pulmonary endometriosis was menstruating 14 months after stopping triptorelin.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableMenstruation after cessation
    Study

    n = 1

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.75 mg/month · intramuscular · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient was then treated with Triptorelin (3.75 mg/month intramuscularly) for 6 months and remains asymptomatic and menstruating 14 months after discontinuing treatment.
    2 context sentences
    Summary · context
    We present two cases of pulmonary endometriosis, parenchymal and pleural.
    Summary · context
    The presenting symptoms were catamenial hemoptysis and pneumothorax, respectively, which were treated with GnRH analogues.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.